HERPESVIRUS VECTORS AS AN AIDS VACCINE

疱疹病毒载体作为艾滋病疫苗

• 批准号: 8357916
• 负责人: Amitinder Kaur
• 金额: $ 19.54万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357916
• 关键词: AIDS Vaccines; DNA; Dose; Funding; Gagging; Grant; Herpesviridae; Immunization; National Center for Research Resources; New England; Primates; Principal Investigator; Recombinants; Research; Research Infrastructure; Resources; SIV Vaccines; Simplexvirus; Source; United States National Institutes of Health; base; cost; protective efficacy; rectal; vector

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. In order to develop an AIDS vaccine, immunization with recombinant replication-defective herpes simplex virus (HSV) d106 vector-based and DNA vector-based SIV vaccines expressing Gag, Env, Rev, Tat, and Nef is being investigated for protective efficacy against homologous high-dose, intra-rectal SIVmac239 challenge.

该子项目是利用资源的众多研究子项目之一 由 NIH/NCRR 资助的中心拨款提供。子项目的主要支持 并且子项目的主要研究者可能是由其他来源提供的， 包括其他 NIH 来源。 子项目可能列出的总成本 代表子项目使用的中心基础设施的估计数量， NCRR 赠款不直接向子项目或子项目工作人员提供资金。 为了开发艾滋病疫苗，正在研究使用表达 Gag、Env、Rev、Tat 和 Nef 的重组复制缺陷型单纯疱疹病毒 (HSV) d106 载体和基于 DNA 载体的 SIV 疫苗进行免疫，以了解其对同源病毒的保护效力。高剂量、直肠内 SIVmac239 攻击。